Metabolic syndrome and inflammation: a critical review of in vitro and clinical approaches for benefit assessment of plant food supplements.
Metabolic syndrome and inflammation: a critical review of in vitro and clinical approaches for benefit assessment of plant food supplements.
复制标题
DOI：
10.1155/2013/782461
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
Restani P
中科院分区：
文献类型：
--
作者：
Di Lorenzo C;Dell'agli M;Colombo E;Sangiovanni E;Restani P
代谢综合征定义为与胰岛素抵抗、2型糖尿病和肥胖相关的多种代谢异常在个体中的聚集，其中通常观察到低度慢性炎症活动。欧洲PlantLIBRA项目的一部分涉及评估植物食品补充剂（PFS）对抗炎症活动和代谢综合征的益处的方法。本文总结了目前用于PFS获益评估的方法，仅考虑了用于研究植物抗炎特性的体外、计算机模拟和临床方法。没有发现与代谢综合征相关的计算机模拟研究（使用计算机模拟）;这些方法似乎专门用于鉴定或测试药物开发中潜在有效的化合物。大多数用于评估植物性药物或植物性食品补充剂对糖尿病有益作用的体外方法都是基于定量聚合酶链反应（PCR），而首选的临床研究是双盲随机对照临床试验。在体外和体内研究中，仅观察到两个参数在植物药治疗后发生变化：白细胞介素-6和肿瘤坏死因子-α，在未来的PFS获益评估研究中应仔细考虑这些生物标志物。
Metabolic syndrome is defined as the clustering in an individual of several metabolic abnormalities associated with insulin resistance, type 2 diabetes, and obesity, in which low-grade chronic inflammatory activity is commonly observed. Part of the European Project PlantLIBRA is concerned with methods to assess the benefits of plant food supplements (PFSs) in countering inflammatory activity and metabolic syndrome. This paper summarizes the current methods used for benefit assessment of PFS, taking into consideration only in vitro, in silico, and clinical methodologies used to investigate the anti-inflammatory properties of plants. No in silico studies (using computer simulation) related to metabolic syndrome were found; these methods appear to be used exclusively for identifying or testing potentially effective compounds in drug development. Most in vitro methods for the assessment of beneficial effects of botanicals or plant food supplements in diabetes were based on a quantitative polymerase chain reaction (PCR), whereas the preferred kind of clinical study was the double-blind randomized controlled clinical trial. Only two parameters were observed to change after treatment with botanicals in both in vitro and in vivo studies: interleukin-6 and tumour necrosis factor-α, and these biomarkers should be carefully considered in future studies for PFS benefit assessment.
登录
查看更多内容
影响因子：
7.1
作者：
Chuang, Chia Chi;Martinez, Kristina;McIntosh, Michael K.
通讯作者：
McIntosh, Michael K.
影响因子：
4.7
作者：
Gagliardi, A. C. M.;Maranhao, R. C.;Santos, R. D.
通讯作者：
Santos, R. D.
影响因子：
5.4
作者：
Fenercioglu, A. Kutan;Saler, T.;Altuntas, Y.
通讯作者：
Altuntas, Y.
影响因子：
6.9
作者：
Bradley, Richard L.;Fisher, FFolliott M.;Maratos-Flier, Eleftheria
通讯作者：
Maratos-Flier, Eleftheria
影响因子：
4.4
作者：
Camargo, Antonio;Ruano, Juan;Perez-Jimenez, Francisco
通讯作者：
Perez-Jimenez, Francisco